Journal of Comprehensive Pediatrics

Published by: Kowsar

The Effects of Glucocorticoids on Bone Strength in Children with Renal Diseases

Jun Aoyagi 1 , Takahiro Kanai 1 , * , Takane Ito 1 , Jun Odaka 1 , Takashi Saito 1 , Hiroyuki Betsui 1 and Takanori Yamagata 1
Authors Information
1 Department of Pediatrics, Jichi Medical University, 3311-1 Yakushiji Shimotsuke Tochigi 329-0498, Japan
Article information
  • Journal of Comprehensive Pediatrics: November 2016, 7 (4); e38727
  • Published Online: November 12, 2016
  • Article Type: Brief Report
  • Received: April 27, 2016
  • Revised: June 29, 2016
  • Accepted: October 23, 2016
  • DOI: 10.17795/compreped-38727

To Cite: Aoyagi J, Kanai T, Ito T, Odaka J, Saito T, et al. The Effects of Glucocorticoids on Bone Strength in Children with Renal Diseases, J Compr Ped. 2016 ; 7(4):e38727. doi: 10.17795/compreped-38727.

Abstract
Copyright © 2016, Iranian Society of Pediatrics. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Hodson EM, Knight JF, Willis NS, Craig JC. Corticosteroid therapy in nephrotic syndrome: a meta-analysis of randomised controlled trials. Arch Dis Child. 2000; 83(1): 45-51[DOI][PubMed]
  • 2. Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004; 15(1): 157-63[DOI][PubMed]
  • 3. Phan V, Blydt-Hansen T, Feber J, Alos N, Arora S, Atkinson S. Skeletal findings in the first 12 months following initiation of glucocorticoid therapy for pediatric nephrotic syndrome. Osteoporosis Int. 2014; 25(2): 627-37
  • 4. Morrison NA, Shine J, Fragonas JC, Verkest V, McMenemy ML, Eisman JA. 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science. 1989; 246(4934): 1158-61[PubMed]
  • 5. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metabol Clin North Am. 2003; 32(1): 135-57
  • 6. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998; 102(2): 274-82[DOI][PubMed]
  • 7. Sbrocchi AM, Rauch F, Matzinger M, Feber J, Ward LM. Vertebral fractures despite normal spine bone mineral density in a boy with nephrotic syndrome. Pediatr Nephrol. 2011; 26(1): 139-42[DOI][PubMed]
  • 8. Biyikli NK, Emre S, Sirin A, Bilge I. Biochemical bone markers in nephrotic children. Pediatr Nephrol. 2004; 19(8): 869-73[DOI][PubMed]
  • 9. Boot AM, de Ridder MA, Pols HA, Krenning EP, de Muinck Keizer-Schrama SM. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. J Clin Endocrinol Metab. 1997; 82(1): 57-62[DOI][PubMed]
  • 10. El-Darouti MA, Mashaly HM, El-Nabarawy E, El-Tawdy AM, Fawzy MM, Salem DS, et al. Comparative study of the effect of a daily steroid regimen versus a weekly oral pulse steroid regimen on morphological changes, blood sugar, bone mineral density and suprarenal gland activity. J Dermatolog Treat. 2012; 23(1): 4-10[DOI][PubMed]
  • 11. Lems WF, Gerrits MI, Jacobs JW, van Vugt RM, van Rijn HJ, Bijlsma JW. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 1996; 55(5): 288-93[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments